Karyopharm Therapeutics Inc. (NASDAQ:KPTI) released its earnings results on Thursday. The company reported ($0.65) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.64) by ($0.01), Bloomberg Earnings reports. Karyopharm Therapeutics had a negative return on equity of 75.03% and a negative net margin of 67,267.47%.
Karyopharm Therapeutics (KPTI) traded up $0.87 on Friday, hitting $11.23. 2,269,911 shares of the company traded hands, compared to its average volume of 175,660. Karyopharm Therapeutics has a 1 year low of $6.27 and a 1 year high of $14.63.
Several research firms have recently issued reports on KPTI. ValuEngine upgraded shares of Karyopharm Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, August 24th. Robert W. Baird reiterated a “buy” rating on shares of Karyopharm Therapeutics in a report on Friday. BidaskClub upgraded shares of Karyopharm Therapeutics from a “strong sell” rating to a “sell” rating in a report on Wednesday, August 9th. Jefferies Group LLC reiterated a “buy” rating on shares of Karyopharm Therapeutics in a report on Friday, October 13th. Finally, Zacks Investment Research lowered shares of Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, July 18th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and seven have issued a buy rating to the stock. Karyopharm Therapeutics has an average rating of “Buy” and a consensus target price of $15.38.
ILLEGAL ACTIVITY WARNING: This news story was reported by Community Financial News and is the property of of Community Financial News. If you are accessing this news story on another publication, it was illegally copied and republished in violation of United States and international trademark and copyright laws. The legal version of this news story can be viewed at https://www.com-unik.info/2017/11/04/karyopharm-therapeutics-inc-kpti-posts-quarterly-earnings-results-misses-expectations-by-0-01-eps.html.
In related news, Director Mansoor Raza Mirza sold 2,882 shares of Karyopharm Therapeutics stock in a transaction on Friday, September 15th. The stock was sold at an average price of $11.00, for a total transaction of $31,702.00. Following the completion of the sale, the director now directly owns 2,882 shares of the company’s stock, valued at $31,702. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Over the last ninety days, insiders have sold 10,695 shares of company stock valued at $118,950. 14.71% of the stock is owned by insiders.
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1.
What are top analysts saying about Karyopharm Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Karyopharm Therapeutics Inc. and related companies.